Seelos Therapeutics, Inc. has ongoing preclinical programs, including SLS-004, SLS-006, and SLS-007. It has filed a voluntary petition under chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the Southern District of New York.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-24	$0.000000	-	2

Delayed Quote OTC Markets

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

Market Closed - OTC Markets Other stock markets 12:25:32 2026-06-01 pm EDT			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		0.00%	-

Dec. 28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI

Market Cap	101K 89.16K 82.24K 76.92K 144K 9.55M 147K 988K 383K 4.71M 380K 372K 16.38M	P/E 2022	-0.98x	P/E 2023	-0.18x
Enterprise Value	11.33M 9.98M 9.2M 8.61M 16.13M 1.07B 16.43M 111M 42.84M 527M 42.55M 41.63M 1.83B	EV / Sales 2022	-	EV / Sales 2023	11,278,456x
Free-Float	88.85%	Yield 2022 *	-	Yield 2023	-

Dec. 28	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-10-21	GLD Partners, LP acquired Select assets from Seelos Therapeutics, Inc. (OTCPK : SEEL.Q).	CI
25-10-14	Motion for Asset Sale Approved for Seelos Therapeutics, Inc.	CI
25-08-15	Bidding Procedure Approved for Seelos Therapeutics, Inc.	CI
25-04-30	Motion for Asset Sale Filed by Seelos Therapeutics, Inc.	CI
25-04-29	Motion for Case Conversion or Dismissal Filed for Seelos Therapeutics, Inc.	CI
24-11-15	Seelos Therapeutics, Inc. Filed for Bankruptcy	CI
24-10-17	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from S&P TMI Index	CI
24-10-15	Top Midday Decliners	MT
24-10-14	Seelos Therapeutics, Inc.(OTCPK:SEEL) dropped from NASDAQ Composite Index	CI
24-09-27	Top Midday Decliners	MT
24-09-24	Seelos Therapeutics, Inc. Announces the Signing of A Material Transfer Agreement with the U.S. Army Medical Materiel Development Activity	CI
24-09-24	Sector Update: Health Care Stocks Mixed Late Afternoon	MT

23-09-21	Benchmark Cuts Price Target on Seelos Therapeutics to $1 From $4, Maintains Speculative Buy Rating	MT
23-09-21	Guggenheim Downgrades Seelos Therapeutics to Neutral From Buy	MT
23-09-21	Cantor Fitzgerald Downgrades Seelos Therapeutics to Neutral From Overweight	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Seelos Therapeutics to $2 From $3, Maintains Overweight Rating	MT
23-03-24	Benchmark Adjusts Price Target on Seelos Therapeutics to $4 From $6, Maintains Buy Rating	MT

Seelos Therapeutics, Inc. Stock

Stocks

SEELQ

US81577F4063

Biotechnology & Medical Research

Valuation: Seelos Therapeutics, Inc.

Chart: Seelos Therapeutics, Inc.

Latest news : Seelos Therapeutics, Inc.

Analysts' recommendations: Seelos Therapeutics, Inc.

Press Releases: Seelos Therapeutics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Seelos Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

24-11-22	Seelos Therapeutics : Late Filing Notice Form NT 10 Q	PU
24-10-24	Seelos Therapeutics : Announces Second Postponement of its Annual Meeting of Stockholders Form 8 K	PU
24-10-24	Seelos Announces Second Postponement of its Annual Meeting of Stockholders	PR
24-10-15	Seelos Therapeutics : Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over the Counter Market Form 8 K	PU
24-10-15	Seelos Therapeutics Announces Notice of Delisting from Nasdaq and Transfer of Listing to Over-the-Counter Market	PR

1 month	0		0
Current year	0		0.01
1 year	0		0.01
3 years	0		6,374.41
5 years	0		11,904.01
10 years	0		28,761.63

Manager	Title	Age	Since
Raj Mehra CEO	Chief Executive Officer	66	2018-12-31
Michael Golembiewski DFI	Director of Finance/CFO	54	2021-08-31
Gopal Krishna CTO	Chief Tech/Sci/R&D Officer	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
24-02-28	Michael Golembiewski	Free	Chief Financial Officer	417	0.0043%
24-01-11	Raj Mehra	Free	Chief Executive Officer	70,383	0.7186%
24-01-11	Michael Golembiewski	Free	Chief Financial Officer	24,537	0.2505%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SEELOS THERAPEUTICS, INC.	+9,900.00%	0.00%	-	-100.00%	136
ARGENX SE	-0.05%	-1.91%	+54.87%	+108.99%	52.88B
WUXI APPTEC CO., LTD.	+8.55%	+17.52%	+72.65%	+82.31%	50.98B
BIONTECH SE	-0.45%	-2.18%	-14.16%	-15.80%	22.81B
INSMED INCORPORATED	+1.28%	+5.09%	-2.30%	+418.34%	22.43B
WUXI BIOLOGICS (CAYMAN) INC.	+2.03%	+7.59%	+29.03%	-13.76%	17.01B
GENMAB A/S	-0.75%	+4.24%	+28.92%	-34.74%	15.91B
EXELIXIS, INC.	+2.98%	+0.82%	+15.64%	+166.21%	13.29B
PHARMAESSENTIA CORPORATION	+5.94%	+14.85%	+134.05%	+296.09%	13.58B
MADRIGAL PHARMACEUTICALS, INC.	-0.71%	+1.98%	+78.88%	+114.48%	11.75B
Average	+991.90%	+4.68%	+44.18%	+102.21%	22.06B
Weighted average by Cap.	+2.67%	+5.40%	+45.96%	+116.79%

	2022	2023
Net sales	-	2.2 1.94 1.79 1.67 3.13 207.65 3.19 21.5 8.33 102.43 8.27 8.09 356.38
Net income	-73.53M -64.74M -59.71M -55.85M -105M -6.93B -107M -718M -278M -3.42B -276M -270M -11.9B	-37.88M -33.35M -30.76M -28.77M -53.91M -3.57B -54.91M -370M -143M -1.76B -142M -139M -6.13B
Net Debt	4.59M 4.04M 3.73M 3.49M 6.53M 433M 6.65M 44.78M 17.35M 213M 17.23M 16.86M 742M	11.23M 9.89M 9.12M 8.53M 15.98M 1.06B 16.28M 110M 42.46M 522M 42.17M 41.26M 1.82B